Dr. Donald Poirier has been a professor at the Department of Molecular Medicine (Faculty of Medicine, Laval University, Québec, Qc) since July 1991 as well as a researcher at the CHU de Québec – Research Center (Québec, Qc). Since 2008, he has also been Director of the Organic Synthesis Service and Co-Director of the Analytical and Medicinal Chemistry Platform.

Professor Poirier received his basic training in organic chemistry (PhD from Laval University, 1980-1985) and subsequently specialized in medicinal chemistry and endocrinology (Postdoctoral studies at the CHUL-Research Center, 1986-1990, CRM fellowship) and more recently in solid phase synthesis of small molecules of therapeutic interest such as steroid derivatives. He is especially interested in the development of steroidogenic enzyme (17b-HSDs, steroid sulfatase, CYP1B1) inhibitors and antitumor agents for the treatment of different cancers (breast, prostate, ovary, pancreatic, and leukemia). As examples, he developed the first non-estrogenic irreversible steroidal inhibitor of 17β-HSD1 for the treatment of breast cancer and endometriosis. He also developed a family of aminosteroid derivatives that inhibited tumor growth in mice for different cancers (breast, ovary, pancreatic, and leukemia).

In addition to the synthesis of small molecules by classical chemistry, he succeeded by developing solid-phase syntheses of C18-steroid (estrane) derivatives as well as C19-steroid (androstane) derivatives that enabled the generation of model libraries of targeted therapeutic compounds. Thus, he developed a diethylsilylacetylenic linker that produces more stable compounds and a sulfamate linker that produces two classes (phenol and sulfamate) of relevant steroidal or nonsteroidal compounds according to cleavage conditions. He is also interested in additional aspects of organic chemistry (synthesis, new methodologies, NMR analysis, etc.) and medicinal chemistry (SAR, molecular modeling, biological assays, etc.). A particularity of his research group is that he is interested in several stages of the development of a new drug: conception, chemical synthesis, in vitro biological tests (enzymatic assays, cell proliferation, etc.) and in vivo (estrogenic activities and androgenic in female and male mice, plasma concentration, metabolic stability, xenografts of cancer cells, etc.).

Professor Poirier has published 220 scientific publications and is the holder of 11 patents and patent applications. He has also been involved in more than 450 oral and poster presentations, as well as conferences as invited speaker.

CHUL
2705, boulevard Laurier
T-4-50
Québec, Québec
Canada G1V 4G2
217 entries « 2 of 22 »

Dutour R, Maltais R, Perreault M, Roy J, Poirier D

Parallel Solid-Phase Synthesis using a New Diethylsilylacetylenic Linker and Leading to Mestranol Derivatives with Potent Antiproliferative Activities on Multiple Cancer Cell Lines.

Journal Article

Anticancer Agents Med Chem, 18 (10), pp. 1469-1481, 2018, ISSN: 1871-5206.

Abstract | Links:

Djigoue GB, Poirier D

Introducing molecular diversity at the C20-position of pregnenolone by the formation of spiro-2-morpholinones

Journal Article

Curr Org Synth, 15 (4), pp. 541-551, 2018, ISSN: 1570-1794.

| Links:

Sang X, Han H, Poirier D, Lin SX

Steroid sulfatase inhibition success and limitation in breast cancer clinical assays: An underlying mechanism.

Journal Article

J Steroid Biochem Mol Biol, 183 , pp. 80-93, 2018, ISSN: 0960-0760.

Abstract | Links:

Lesperance M, Barbeau X, Roy J, Maltais R, Lague P, Poirier D

Chemical synthesis of C3-oxiranyl/oxiranylmethyl-estrane derivatives targeted by molecular modeling and tested as potential inhibitors of 17β-hydroxysteroid dehydrogenase type 1.

Journal Article

Steroids, 140 , pp. 104-113, 2018, ISSN: 0039-128X.

Abstract | Links:

Boutin S, Poirier D

Structure confirmation and evaluation of a nonsteroidal inhibitor of 17 beta-hydroxysteroid dehydrogenase type 10

Journal Article

Magnetochemistry, 4 (3), pp. 4030043 (10 pages), 2018.

| Links:

Trottier A, Maltais R, Ayan D, Barbeau X, Roy J, Perreault M, Poulin R, Lague P, Poirier D

Insight into the mode of action and selectivity of PBRM, a covalent steroidal inhibitor of 17β-hydroxysteroid dehydrogenase type 1.

Journal Article

Biochem Pharmacol, 144 , pp. 149-161, 2017, ISSN: 0006-2952.

Abstract | Links:

Dutour R, Cortes-Benitez F, Roy J, Poirier D

Structure-Based Design and Synthesis of New Estrane-Pyridine Derivatives as Cytochrome P450 (CYP) 1B1 Inhibitors.

Journal Article

ACS Med Chem Lett, 8 (11), pp. 1159-1164, 2017.

Abstract | Links:

Dutour R, Poirier D

Inhibitors of cytochrome P450 (CYP) 1B1.

Journal Article

Eur J Med Chem, 135 , pp. 296-306, 2017, ISSN: 0223-5234.

Abstract | Links:

Cortes-Benitez F, Roy J, Maltais R, Poirier D

Impact of androstane A- and D-ring inversion on 17β-hydroxysteroid dehydrogenase type 3 inhibitory activity, androgenic effect and metabolic stability.

Journal Article

Bioorg Med Chem, 25 (7), pp. 2065-2073, 2017, ISSN: 0968-0896.

Abstract | Links:

Perreault M, Maltais R, Roy J, Dutour R, Poirier D

Design of a Mestranol 2-N-Piperazino-Substituted Derivative Showing Potent and Selective in vitro and in vivo Activities in MCF-7 Breast Cancer Models.

Journal Article

ChemMedChem, 12 (2), pp. 177-182, 2017, ISSN: 1860-7179.

Abstract | Links:

217 entries « 2 of 22 »
Signaler des ajouts ou des modifications

Active projects

  • Centres hospitaliers universitaires de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Démonstration de l'efficacité du premier inhibiteur irréversible et sélectif de la 17beta-HSD1 pour le traitement des cancers du sein sensibles aux estrogènes, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2018-04-01 to 2020-03-31
  • Développement d’un traitement sélectif de l’endométriose : Étude du potentiel du premier inhibiteur irréversible de la 17beta-HSD1 chez le primate, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2017-04-01 to 2019-09-30

Recently finished projects

  • Centre de recherche en endocrinologie, métabolisme et inflammation, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-06-01 to 2018-04-30
  • Valorisation de l'aminostéroïde RM-581 comme traitement novateur contre le cancer avancé de la prostate., Subvention, Fondation du CHU de Québec, from 2017-11-21 to 2019-03-31
Data provided by the Université Laval research projects registery